UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 104

Layers, RJ (1989). Prescription charges, the demand for prescriptions and morbidity.
Applied economics , 21(8).
Le Pen, C (2003). The drug budget silo mentality: the French case. Value in Health ,6
(Suppl 1), S10-S19.
Leibowitz, A, WG Manning and JP Newhouse (1985). The demand for prescription drugs
as a function of cost-sharing. Social Science & Medicine , 21(10), 1063-1069.
Lexchin, J and P Grootendorst (2004). Effects of prescription drug user fees on drug and
health services use and on health status in vulnerable populations: a systematic review
of the evidence. International Journal of Health Services , 34(1), 101-122.
Lichtenberg, F (2002). Benefits and costs of newer drugs an update. NBER Working Paper
No. 8996.
Ljungkvist, MO, D Andersson and B Gunnarsson (1997). Cost and utilisation of pharma-
ceuticals in Sweden. Health Policy , 41(Suppl 1), S55-S69.
Lopez-Casasnovas, G and J Puig-Junoy (2000). Review of the literature on reference pricing.
Health Policy , 54(2), 87-123.
Lundkvist, J (2002). Pricing and reimbursement of drugs in Sweden. European Journal of
Health Economics , 3(1), 66-70.
Lyles, A and FB Palumbo (1999). The effect of managed care on prescription drug costs
and benefits. Pharmacoeconomics , 15(2), 129-140.
Mace, S and D Taylor (2003). Adherence to NICE guidance for the use of anti-
cholinesterases. Disease Management & Health Outcomes , 11(2), 129-137.
Marshall, JK et al . (2002). Impact of reference-based pricing for histamine-2 receptor antag-
onists and restricted access for proton pump inhibitors in British Columbia. Canadian
Medical Association Journal , 166(13), 1655-1662.
Maxwell, M et al . (1993). General practice fundholding: observations on prescribing
patterns and costs using the defined daily dose method. British Medical Journal ,
307(6913), 1190-1194.
McCombs, JS, P Mulani and PJ Gibson (2004). Open access to innovative drugs: treat-
ment substitutions or treatment expansion? Health Care Financing Review , 25(3),
35-53.
McGuire, A and M Litt (2003). UK budgetary systems and new health-care technologies.
Value in Health , 6 (Suppl 1), S64-S73.
Mrazek, MF and E Mossialos (2004). Regulating pharmaceutical prices. In Regulating
Pharmaceuticals in Europe: striving for Efficiency, Equity ; E Mossialos, T Walley
and MF Mrazek (eds.). London: the European Observatory on Health Systems and
Policies, Brussels, and Open University Press.
Murray, MD and FW Deardorff (1998). Does managed care fuel pharmaceutical industry
growth? Pharmacoeconomics , 14(4), 341-348.
Oliver, A, E Mossialos and R Robinson (2004). Health technology assessment and its influ-
ence on health-care priority setting. International Journal of Technology Assessment
in Health Care , 20(1), 1-10.
Pavcnik, N (2000). Do pharmaceutical prices respond to insurance? NBER Working Papers
# 7865.